Standard adjuvant polychemotherapy for patients with breast cancer significantly improves their survival and is used for this patient group worldwide. In the beginning of this era, mainly CMF (cyclophosphamide, methotrexate and fluorouracil) was used but CMF is nowadays often replaced by anthracycline containing regimens after results favoring anthracyclines were published. The role of taxanes in the adjuvant setting is not yet fully understood; however, this should become clearer following the results from several ongoing randomized studies. In addition to the question of which drugs to use, dosage recommendations are a more complex issue. Low dosage regimens have been associated with inferior survival results compared with standard dosages in the adjuvant setting. High dosage regimens of anthracyclines have not been associated with better survival in some studies, although some investigators have shown the opposite. The use of very high doses requiring autologous bone marrow support have not resulted in survival gains in randomized studies.
American Journal of Cancer – Springer Journals
Published: Aug 9, 2012